Rashmi Kanagal-Shamanna

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1355244/publications.pdf

Version: 2024-02-01

160 papers	7,219 citations	93792 39 h-index	78623 77 g-index
167 all docs	167 docs citations	167 times ranked	7455 citing authors

#	Article	IF	Citations
1	Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. Blood Advances, 2023, 7, 828-831.	2.5	1
2	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. Journal of Clinical Oncology, 2022, 40, 202-212.	0.8	34
3	Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplantation, 2022, 57, 370-376.	1.3	8
4	Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts. Leukemia, 2022, 36, 1189-1192.	3.3	5
5	<scp>Nonâ€coding NOTCH1</scp> mutations in chronic lymphocytic leukemia negatively impact prognosis. American Journal of Hematology, 2022, 97, .	2.0	1
6	Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genetics in Medicine, 2022, 24, 986-998.	1.1	55
7	Ibrutinibâ€“rituximab followed by R-HCVAD as frontline treatment for young patients (â‰¤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncology, The, 2022, 23, 406-415.	5.1	22
8	Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leukemia Research, 2022, 116, 106827.	0.4	1
9	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567.	15.2	26
10	TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood, 2022, 140, 58-72.	0.6	46
11	High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Advances, 2022, 6, 4006-4014.	2.5	37
12	Optical genome mapping for structural variation analysis in hematologic malignancies. American Journal of Hematology, 2022, 97, 975-982.	2.0	20
13	Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Modern Pathology, 2022, 35, 1212-1219.	2.9	10
14	Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood, 2022, 140, 1753-1763.	0.6	56
15	TP53â€altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitorâ€based therapy: A retrospective analysis. American Journal of Hematology, 2022, 97, 1005-1012.	2.0	6
16	A community approach to the cancer-variant-interpretation bottleneck. Nature Cancer, 2022, 3, 522-525.	5.7	3
17	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/DendriticÂNeoplasms. Leukemia, 2022, 36, 1703-1719.	3.3	1,211
18	Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia. Leukemia, 2022, 36, 2097-2107.	3.3	2

#	Article	IF	Citations
19	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2022, 40, 3848-3857.	0.8	41
20	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E50-E53.	2.0	8
21	Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia â€“ a distinct subtype with favorable prognosis. Leukemia and Lymphoma, 2021, 62, 224-228.	0.6	6
22	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Blood Cancer Discovery, 2021, 2, 125-134.	2.6	50
23	The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. American Journal of Hematology, 2021, 96, 241-250.	2.0	19
24	Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. Modern Pathology, 2021, 34, 854-861.	2.9	9
25	Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3 â€ITD and IDH mutations. Cancer, 2021, 127, 381-390.	2.0	10
26	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1â€mutated acute myeloid leukaemia. British Journal of Haematology, 2021, 192, 1054-1063.	1.2	28
27	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer Journal, 2021, 11, 18.	2.8	8
28	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology, 2021, 96, E137-E140.	2.0	6
29	Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leukemia Research, 2021, 101, 106511.	0.4	4
30	Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer Journal, 2021, 11, 52.	2.8	5
31	Longâ€term followâ€up of salvage therapy using a combination of inotuzumab ozogamicin and miniâ€“hyperâ€CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. Cancer, 2021, 127, 2025-2038.	2.0	24
32	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<scp>MDS/MPNâ€RSâ€T</scp>) and myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>). American Journal of Hematology, 2021, 96, E246-E249.	2.0	9
33	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer, 2021, 127, 3113-3124.	2.0	5
34	Prognostic factors for progression in patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer, 2021, 127, 2648-2656.	2.0	33
35	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 1494-1499.	3.3	16
36	<scp>FLT3</scp> inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed <scp>Acute Myeloid Leukemia</scp> with very low <scp>FLT3</scp> allelic burden. American Journal of Hematology, 2021, 96, E275-E279.	2.0	3

#	Article	IF	Citations
37	The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition. Current Hematologic Malignancy Reports, 2021, 16, 336-344.	1.2	6
38	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia, 2021, 35, 3421-3429.	3.3	22
39	Longâ€term results of lowâ€intensity chemotherapy with clofarabine or cladribine combined with lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2021, 96, 914-924.	2.0	13
40	Outcomes in patients with newly diagnosed TP53â€mutated acute myeloid leukemia with or without venetoclaxâ€based therapy. Cancer, 2021, 127, 3541-3551.	2.0	40
41	Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer, 2021, 127, 3552-3565.	2.0	19
42	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. JAMA Oncology, 2021, 7, 1213.	3.4	53
43	Development of <scp>TP53</scp> mutations over the course of therapy for acute myeloid leukemia. American Journal of Hematology, 2021, 96, 1420-1428.	2.0	10
44	EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Modern Pathology, 2021, 34, 2183-2191.	2.9	7
45	Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies. Frontiers in Oncology, 2021, 11, 748250.	1.3	7
46	Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia. Leukemia Research, 2021, 108, 106616.	0.4	2
47	Mantle cell lymphoma involving tonsils: a clinicopathologic study of 83 cases. Human Pathology, 2021, 118, 60-68.	1.1	4
48	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	2.9	9
49	Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia. Leukemia and Lymphoma, 2021, , 1-11.	0.6	0
50	Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. American Journal of Hematology, 2020, 95, 227-229.	2.0	29
51	Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia. Cancer, 2020, 126, 765-774.	2.0	69
52	RAS and TP53 can predict survival in adults with Tâ€cell lymphoblastic leukemia treated with hyperâ€CVAD. Cancer Medicine, 2020, 9, 849-858.	1.3	9
53	Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. Leukemia and Lymphoma, 2020, 61, 2980-2984.	0.6	3
54	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). American Journal of Hematology, 2020, 95, E326-E329.	2.0	2

#	Article	IF	Citations
55	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. American Journal of Hematology, 2020, 95, E313-E315.	2.0	4
56	Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Advances, 2020, 4, 5681-5689.	2.5	105
57	Impact of <scp>CD33</scp> and <scp>ABCB1</scp> single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. American Journal of Hematology, 2020, 95, E225-E228.	2.0	9
58	Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. Current Hematologic Malignancy Reports, 2020, 15, 194-202.	1.2	7
59	Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer Journal, 2020, 10, 61.	2.8	20
60	Nucleophosmin 1 Mutations in Acute Myeloid Leukemia. Genes, 2020, 11, 649.	1.0	29
61	Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Modern Pathology, 2020, 33, 1678-1689.	2.9	16
62	Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. American Journal of Hematology, 2020, 95, 612-622.	2.0	51
63	LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leukemia and Lymphoma, 2020, 61, 1493-1499.	0.6	14
64	A heavy metal baseline score predicts outcome in acute myeloid leukemia. American Journal of Hematology, 2020, 95, 422-434.	2.0	12
65	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) â€•outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients. American Journal of Hematology, 2020, 95, 623-629.	2.0	54
66	Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Advances, 2020, 4, 1670-1677.	2.5	24
67	Evidence-based review of genomic aberrations in B-lymphoblastic leukemia/lymphoma: Report from the cancer genomics consortium working group for lymphoblastic leukemia. Cancer Genetics, 2020, 243, 52-72.	0.2	14
68	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Advances, 2020, 4, 482-495.	2.5	86
69	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances, 2020, 4, 1038-1050.	2.5	43
70	Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Frontiers in Oncology, 2020, 10, 582213.	1.3	33
71	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood, 2020, 136, 42-43.	0.6	11
72	Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood, 2020, 136, 17-19.	0.6	10

#	Article	IF	Citations
73	Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups. Blood, 2020, 136, 20-22.	0.6	0
74	Hypomethylating Agents Do Not Alter Novel Splicing Events in Myeloid Neoplasms. Blood, 2020, 136, 37-38.	0.6	0
75	Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression. Blood, 2020, 136, 19-20.	0.6	0
76	Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series. Blood, 2020, 136, 18-19.	0.6	2
77	Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma. Blood, 2020, 136, 41-42.	0.6	0
78	Expert Variant Curation Combined with in-Silico analysis for Clinical Interpretation of BCL2 variants in Resistance to BCL2 Inhibitors in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma. Blood, 2020, 136, 42-43.	0.6	0
79	Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab. Blood, 2020, 136, 31-32.	0.6	2
80	Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with NPM1-mutated Acute Myeloid Leukemia. Blood, 2020, 136, 38-39.	0.6	1
81	Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors - Comprehensive Analysis of 396 Patients. Blood, 2020, 136, 32-33.	0.6	2
82	Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT). Blood, 2020, 136, 23-23.	0.6	0
83	MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 37-48.	0.6	54
84	Association of gene mutations with timeâ€toâ€first treatment in 384 treatmentâ€naive chronic lymphocytic leukaemia patients. British Journal of Haematology, 2019, 187, 307-318.	1.2	26
85	Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. Leukemia Research, 2019, 84, 106176.	0.4	7
86	Ibrutinib and Venetoclax for First-Line Treatment of CLL. New England Journal of Medicine, 2019, 380, 2095-2103.	13.9	388
87	Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent <scp>CD</scp>33 expression and in vitro response to targeted <scp>CD</scp>33 therapy. British Journal of Haematology, 2019, 186, 538-548.	1.2	21
88	TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Annals of Diagnostic Pathology, 2019, 41, 38-42.	0.6	18
89	Clonal hematopoiesis of indeterminate potentialâ€“associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer, 2019, 125, 2233-2241.	2.0	19
90	DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and highâ€risk disease. American Journal of Hematology, 2019, 94, 757-766.	2.0	86

#	Article	IF	Citations
91	Routine sequencing in <scp>CLL</scp> has prognostic implications and provides new insight into pathogenesis and targeted treatments. British Journal of Haematology, 2019, 185, 852-864.	1.2	19
92	Rational â€œError Eliminationâ€•Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies. Journal of Molecular Diagnostics, 2019, 21, 471-482.	1.2	1
93	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Advances, 2019, 3, 922-933.	2.5	84
94	Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica, 2019, 104, 305-311.	1.7	56
95	Ultra-Rapid Reporting of GENomic Targets (URGENTseq). Journal of Molecular Diagnostics, 2019, 21, 89-98.	1.2	23
96	Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematology,the, 2019, 6, e29-e37.	2.2	84
97	Leukemic Involvement in the Thorax. Radiographics, 2019, 39, 44-61.	1.4	38
98	Co-occurrence of chronic myeloid leukemia with chronic lymphocytic leukemia: a report of two cases. Leukemia and Lymphoma, 2019, 60, 1568-1571.	0.6	7
99	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitorâ€“resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer, 2019, 125, 559-574.	2.0	70
100	Improving the detection of patients with inherited predispositions to hematologic malignancies using nextâ€generation sequencingâ€based leukemia prognostication panels. Cancer, 2018, 124, 2704-2713.	2.0	39
101	Outcomes with lower intensity therapy inTP53-mutated acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2238-2241.	0.6	20
102	The absolute percent deviation of <scp>IGHV</scp> mutation rather than a 98% cutâ€off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. British Journal of Haematology, 2018, 180, 33-40.	1.2	33
103	Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group. Cancer Genetics, 2018, 228-229, 218-235.	0.2	21
104	Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. Current Hematologic Malignancy Reports, 2018, 13, 467-476.	1.2	4
105	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Cancer Genetics, 2018, 228-229, 197-217.	0.2	25
106	Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. Cancer Genetics, 2018, 228-229, 236-250.	0.2	26
107	Longâ€term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. British Journal of Haematology, 2018, 183, 578-587.	1.2	81
108	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Advances, 2018, 2, 1807-1816.	2.5	34

#	Article	IF	Citations
109	Fourâ€year followâ€up of a single arm, phase <scp>II</scp> clinical trial of ibrutinib with rituximab (<scp>IR</scp>) in patients with relapsed/refractory mantle cell lymphoma (<scp>MCL</scp>). British Journal of Haematology, 2018, 182, 404-411.	1.2	50
110	Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Modern Pathology, 2018, 31, 1717-1732.	2.9	30
111	P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapseâ€free survival. American Journal of Hematology, 2018, 93, 1376-1383.	2.0	17
112	Cell-Type Specific Mechanisms of Hematopoietic Stem Cell (HSC) Expansion Underpin Progressive Disease in Myelodysplastic Syndromes (MDS) and Provide a Rationale for Targeted Therapies. Blood, 2018, 132, 1798-1798.	0.6	4
113	Characterization of TP53 mutations in clonal cytopenia of undetermined significance. American Journal of Hematology, 2017, 92, E175-E177.	2.0	4
114	Validation of the 2016 revisions to the <scp>WHO</scp> classification in lowerâ€risk myelodysplastic syndrome. American Journal of Hematology, 2017, 92, E168-E171.	2.0	5
115	TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyperâ€CVADâ€based regimens. Cancer, 2017, 123, 3717-3724.	2.0	18
116	Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer, 2017, 123, 4391-4402.	2.0	114
117	Clinical characteristics and outcomes of previously untreated patients with adult onset Tâ€acute lymphoblastic leukemia and Tâ€lymphoblastic lymphoma with hyperâ€CVAD based regimens. American Journal of Hematology, 2017, 92, E595-E597.	2.0	8
118	Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica, 2017, 102, 1661-1670.	1.7	64
119	Targeted therapyâ€“induced differentiation of acute myeloid leukemia blasts. Blood, 2017, 129, 3503-3503.	0.6	2
120	Synchronous presentation of intraâ€nodal follicular dendritic cell sarcoma and Castleman disease. American Journal of Hematology, 2017, 92, 478-479.	2.0	8
121	Refractory hairy cell leukemiaâ€variant. American Journal of Hematology, 2017, 92, 1398-1399.	2.0	2
122	Metastatic rhabdomyosarcoma initially diagnosed on the bone marrow. Blood, 2016, 128, 2189-2189.	0.6	1
123	Advances in B-lymphoblastic leukemia: cytogenetic and genomic lesions. Annals of Diagnostic Pathology, 2016, 23, 43-50.	0.6	11
124	Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood, 2016, 127, 1269-1275.	0.6	119
125	Systemic AL amyloidosis associated with WaldenstrÃ¶m macroglobulinemia: an unusual presenting complication. Blood, 2016, 127, 168-168.	0.6	5
126	TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer, 2016, 122, 3484-3491.	2.0	200

#	Article	IF	Citations
127	Crystalâ€storing histiocytosis: a clinicopathological study of 13 cases. Histopathology, 2016, 68, 482-491.	1.6	60
128	Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult Bâ€cell acute lymphoblastic leukemia (Bâ€ALL) with TET2 and TP53 mutations. American Journal of Hematology, 2016, 91, 354-355.	2.0	3
129	Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Review of Molecular Diagnostics, 2016, 16, 461-472.	1.5	33
130	Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. American Journal of Clinical Pathology, 2016, 145, 418-427.	0.4	6
131	Advances in clinical next-generation sequencing: target enrichment and sequencing technologies. Expert Review of Molecular Diagnostics, 2016, 16, 357-372.	1.5	63
132	Complete Surgical Excision Is Essential for the Management of Patients With Breast Implantâ€“Associated Anaplastic Large-Cell Lymphoma. Journal of Clinical Oncology, 2016, 34, 160-168.	0.8	349
133	Emulsion PCR: Techniques and Applications. Methods in Molecular Biology, 2016, 1392, 33-42.	0.4	13
134	Digital PCR: Principles and Applications. Methods in Molecular Biology, 2016, 1392, 43-50.	0.4	48
135	Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget, 2016, 7, 14251-14258.	0.8	42
136	Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood, 2015, 125, 3360-3363.	0.6	22
137	Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leukemia Research, 2015, 39, 348-354.	0.4	115
138	Therapy-Related Myeloid Neoplasms. American Journal of Clinical Pathology, 2015, 144, 207-218.	0.4	25
139	Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Modern Pathology, 2015, 28, 1014-1022.	2.9	20
140	Utility of Quantitative Flow Cytometry Immunophenotypic Analysis of CD5 Expression in Small B-Cell Neoplasms. Archives of Pathology and Laboratory Medicine, 2014, 138, 903-909.	1.2	13
141	Quantitative Assessment of Mutant Allele Burden in Solid Tumors by Semiconductor-Based Next-Generation Sequencing. American Journal of Clinical Pathology, 2014, 141, 559-572.	0.4	20
142	Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica, 2014, 99, 465-473.	1.7	165
143	Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Modern Pathology, 2014, 27, 314-327.	2.9	196
144	Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood, 2014, 123, 2645-2651.	0.6	192

#	Article	IF	Citations
145	Differential Expression of CD200 in B-Cell Neoplasms by Flow Cytometry Can Assist in Diagnosis, Subclassification, and Bone Marrow Staging. American Journal of Clinical Pathology, 2014, 142, 837-844.	0.4	66
146	Breast Implantâ€“Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients. Journal of Clinical Oncology, 2014, 32, 114-120.	0.8	338
147	Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. Breast Cancer Research and Treatment, 2014, 147, 1-14.	1.1	131
148	Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes. Journal of Molecular Diagnostics, 2013, 15, 607-622.	1.2	314
149	Donor-derived isolated del(20q) after hematopoietic stem cell transplantation: report of two cases and review of the literature. Journal of Hematopathology, 2013, 6, 25-32.	0.2	3
150	Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q). Cancer Genetics, 2013, 206, 42-46.	0.2	16
151	Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Human Pathology, 2013, 44, 110-121.	1.1	31
152	Differential expression of aurora-A kinase in T-cell lymphomas. Modern Pathology, 2013, 26, 640-647.	2.9	25
153	MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma. Advances in Anatomic Pathology, 2013, 20, 315-326.	2.4	72
154	Phenotypic evolution in a case of peripheral Tâ€cell lymphoma suggests the presence of tumor heterogeneity. Journal of Cutaneous Pathology, 2013, 40, 573-579.	0.7	5
155	Classical Hodgkin Lymphoma Arising in the Setting of Iatrogenic Immunodeficiency. American Journal of Surgical Pathology, 2013, 37, 1290-1297.	2.1	38
156	Splenic B-cell lymphomas with more than 55% prolymphocytes in blood: evidence for prolymphocytoid transformation. Human Pathology, 2012, 43, 1828-1838.	1.1	29
157	Over-Expression of CYP2E1 mRNA and Protein: Implications of Xenobiotic Induced Damage in Patients with De Novo Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFÎ²-MYH11. International Journal of Environmental Research and Public Health, 2012, 9, 2788-2800.	1.2	4
158	Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wildâ€typeTP53. Cancer, 2012, 118, 2879-2888.	2.0	68
159	Highâ€grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology, 2012, 61, 945-954.	1.6	44
160	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Modern Pathology, 0, , .	2.9	0